Nampt-IN-3
Product Specifications
UNSPSC Description
Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death[1].
Target Antigen
Apoptosis; Autophagy; HDAC; NAMPT
Type
Reference compound
Related Pathways
Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nampt-in-3.html
Purity
98.97
Solubility
DMSO : 130 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(C2=CN(CC3=CC=C(C(NC4=CC=CC=C4N)=O)C=C3)N=N2)C=C1)NCC5=CC=CN=C5
Molecular Weight
503.55
References & Citations
[1]Dong G, et al. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. J Med Chem. 2017 Oct 12;60(19):7965-7983.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-108701/Nampt-IN-3-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-108701/Nampt-IN-3-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2121591-52-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
